MOUNTAIN VIEW, Calif., June 12, 2012 /PRNewswire/ -- Current optical imaging technologies provide reproducible, accurate, objective, quantitative assessments of tissue structures. As the marked progress in optical imaging techniques observed in recent years is instigating a new wave of business opportunities, there are still areas to improve.
Analysis from Frost & Sullivan's (http://www.technicalinsights.frost.com) Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging research finds that optical imaging at both the macroscopic and microscopic levels is being used intensively by clinicians for diagnosis and treatment-specific applications. Novel advances in optics, data acquisition methods, and image processing software have driven the development of optical imaging technologies, all of which can be used to image tissues and other biological entities with enhanced contrast and resolution capabilities.
If you are interested in more information on this research, please send an email to Britni Myers, Corporate Communications, at [email protected], with your full name, company name, job title, telephone number, company email address, company website, city, state and country.
"Technology trends are moving from conventional confocal microscopy to optical coherence tomography (OCT), with the adoption of newer technologies such as adaptive optics and polarization imaging in ophthalmology," said Technical Insights Senior Research Analyst Prasanna Vadhana Kannan. "Several start-ups are developing innovative technologies, most of which are in the near completion and advanced phases of clinical approval in the optical imaging market."
OCT has gained much multidisciplinary research interest in recent years as a non-invasive optical imaging technique that can be used to perform cross-sectional in-situ imaging of microstructures in biological tissues. With OCT technology showing rapid progress, it is believed that many commercial devices addressing a plethora of clinical applications could hit the market over the next four to five years.
"OCT is truly an easy-to-use modality that provides digital cellular 2-D and 3-D imaging solutions for clinical and research pathology lab application needs on fixed or fresh tissue," said Prasanna Kannan. "Further refinement could result in achieving significantly higher resolution capabilities and better differentiation of cancerous lesions, embryology studies, and stem cells (involving therapeutics research)."
However, the restricted availability of validated imaging parameters and low end-user awareness could limit the use of optical imaging technologies in research-specific applications. Moreover, the scope for alternative techniques usage and their strong presence (involving digital radiography, nuclear imaging techniques, and hybrid imaging) is likely to deter manufacturers from investing substantially in the development of novel optical imaging methods.
"From a technical standpoint, the key challenge is to address issues related to frozen sections arising from tissue processing steps," said Prasanna Kannan. "This often results in freezing artifacts, which causes physical destruction of the structural integrity of tissues."
Despite such challenges, multi-modality imaging using optical imaging principles is helping drive the development of novel therapeutics and changing the course of patient management in debilitating disease care.
Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging is part of the Technical Insights subscription which also includes research on key optical imaging segments, consisting of optical coherence tomography, hyperspectral imaging, and near-infrared spectroscopy analyses. Further, this research service includes detailed technology analysis and industry trends evaluated following extensive interviews with market participants.
Technical Insights is an international technology analysis business that produces a variety of technical news alerts, newsletters and research services.
About Frost & Sullivan
Frost & Sullivan, the Growth Partnership Company, works in collaboration with clients to leverage visionary innovation that addresses the global challenges and related growth opportunities that will make or break today's market participants.
Our "Growth Partnership" supports clients by addressing these opportunities and incorporating two key elements driving visionary innovation: The Integrated Value Proposition and The Partnership Infrastructure.
- The Integrated Value Proposition provides support to our clients throughout all phases of their journey to visionary innovation including: research, analysis, strategy, vision, innovation and implementation.
- The Partnership Infrastructure is entirely unique as it constructs the foundation upon which visionary innovation becomes possible. This includes our 360 degree research, comprehensive industry coverage, career best practices as well as our global footprint of more than 40 offices.
For more than 50 years, we have been developing growth strategies for the global 1000, emerging businesses, the public sector and the investment community. Is your organization prepared for the next profound wave of industry convergence, disruptive technologies, increasing competitive intensity, Mega Trends, breakthrough best practices, changing customer dynamics and emerging economies?
Emerging Trends in Optical Imaging Techniques for Drug Discovery, Clinical Diagnostics and Molecular Imaging
Corporate Communications – North America
E: [email protected]
SOURCE Frost & Sullivan